Investorideas.com newswire, breaking news for marijuana, cannabis and hemp stocks

Monday, 29 July 2019

Investorideas.com - Cannabis Stock News: Tree of Knowledge (CSE: TOKI) (OTCQB: TOKIF) Enters International Distribution Agreement with Cannenta, Expanding Reach into Australia and New Zealand

Investorideas.com - Cannabis Stock News: Tree of Knowledge (CSE: TOKI) (OTCQB: TOKIF) Enters International Distribution Agreement with Cannenta, Expanding Reach into Australia and New Zealand

Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move (CSE: $EASY.C) (CSE: $PLTH.C) (NYSE: $APHA) (CSE: $HITI.C) (CSE: $SOL.C)


Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move (CSE: $EASY.C) (CSE: $PLTH.C) (NYSE: $APHA) (CSE: $HITI.C) (CSE: $SOL.C)





Delta, Kelowna, BC –July 29, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca  release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:



Today’s podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com “Potcast” featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today’s podcast we look at a few early announcements.

SpeakEasy Cannabis Club Ltd. (CSE: EASY) announced that the Company has completed moving its diverse and massive in scale genetics into its facility in anticipation of receiving its cultivation licence in the near future.   Fulfilling the requirement of having genetics present in the facility at the time of licensing, SpeakEasy followed Health Canada's Cannabis Regulations to the letter.  In addition to following federally mandated Cannabis Regulations, SpeakEasy consulted with provincial and municipal governments, as well, as its local RCMP to ensure proper procedures were followed, prior to any movement of the genetics being completed.

SpeakEasy has accumulated an impressive library of unique genetics from sources outside existing License Holders, that will be used as starting material and are currently secured within the facility. The current genetics catalogue spans the full spectrum, providing the ability to produce a wide range of product grown both indoor and outdoor, as well as, permitting the ability to develop new strains, unique to SpeakEasy.  "We believe we have one of the largest genetics libraries in the industry, we are very fortunate to have such incredible partnerships with industry professionals and genetics experts," said Patrick Geen, Head Grower.

The company’s outdoor cultivation site stands ready to receive starting material, upon granting of their initial cultivation license the company plans to immediately submit their evidence package for their outdoor field to amend their license to allow for an outdoor cultivation area on their 60 acre field.
"Going from a cherry orchard, which has laid fallow for years, to a built out outdoor cultivation area ready for growing cannabis in four and a half months has been an incredible achievement, I am so proud of everyone in the SpeakEasy family for their extraordinary efforts and accomplishments," added Bin Huang, CEO.

SpeakEasy also announced that it has hired former RCMP officer Grant Bernier.  Upon Mr. Bernier's security clearance through Health Canada, he will assume the position of Chief Security Officer.  With his appointment, the Company aims to set a new standard in compliance within the industry. Grant will have the authority to preform independent audits within the Company and will have complete autonomy. We believe once this system is in place it will set the standard for compliance in the industry. "We have the utmost confidence that our products will be second to none and we will continue to strive to ensure that it will remain that way.  Additionally, it's exciting to know our Company from top to bottom, will become the cornerstone of exemplary industry standards," said Zena Prokosh, SpeakEasy's QAP.

Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNHF) announced that it has added HaHa Gummies™ and Dreamland Chocolates™ to its growing in-house brand portfolio.
HaHa Gummies and Dreamland Chocolates along with Medizin, TRENDI and Leaf & Vine will be produced in Planet 13's new 15,000 sq. ft. customer-facing production facility located at the Planet 13 Las Vegas Cannabis Entertainment Complex.
Planet 13 in-house brands currently represent approximately 15% of all products sold at the SuperStore. With the opening of the new production facility, Planet 13 intends to continue to grow the in-house brand penetration with a long-term, sustainable target of approximately 50%. Planet 13 also plans to leverage its current SuperStore supplier relationships to gain rapid access for its in-house brands, to premium shelf space in third-party Nevada dispensaries.
"Edibles, especially premium sativa-based edibles, have been very popular with our tourist customer base," said Larry Scheffler, Co-CEO of Planet 13. "HaHa Gummies™ and Dreamland Chocolates™ were designed from the ground up using the customer insights we have generated from the over 400,000 people we have served at the SuperStore in just eight months. We expect that the combination of this deep customer connection and an interactive production experience at the SuperStore will quickly make both brands Nevada favorites.
The Company's Phase II expansion, which includes; coffee shop, bistro, customer-facing production facility, and event space, is expected to open by the end of Q3. Ongoing permitting delays have impacted the construction schedule.  Construction on Phase II is progressing at a solid pace and will accelerate once the final permits are issued.
Bob Groesbeck, Co-CEO of Planet 13, commented, "Despite ongoing permitting delays our goal is to open Phase II by the end of Q3 and to enter the wholesale market in Q4 2019."

Aphria Inc. (TSX: APHA) (NYSE: APHA) today announced that its subsidiary Marigold Projects Jamaica Limited has received a retail Herb House licence from Jamaica's Cannabis Licensing Authority ("CLA") to open its first store in Kingston, Jamaica.

Sensi Medical Cannabis House will be located at the Peter Tosh Square, Unit #51, (yes, it is there), Pulse Center, 38a Trafalgar Road, overlooking the Peter Tosh Museum in New Kingston. The Cannabis House will have a smoking lounge for on-site consumption, high-end accessories for sale, and feature Marigold proprietary strains of cannabis and brands called Sensi Gold.

"The approval of Marigold's first Herb House signals an exciting time for Aphria. We believe that there is tremendous opportunity in Jamaica from a domestic and international perspective and we look forward to bringing Sensi products to the market," said Irwin D. Simon. "Receiving this licence is testament to our team's hard work and dedication in growing our Caribbean and LATAM business as we provide high-quality cannabis products in regions. Aphria will continue to execute on our business plan to create long-term value, sales growth, and profitably in Canada and internationally."

Marigold Projects, a 49 per cent owned subsidiary of Aphria Inc., holds a Tier 3 licence to cultivate more than 5-acres of land with cannabis for medical, scientific and therapeutic purposes. Marigold Projects cultivation farm is fully operational, and inventory at opening will exceed 2,700 kgs. The company maintains an additional 20-acres of vacant land in anticipation of expanding its cultivation operations, as well as a 10-acre farm in St Catherine.

Sensi Medical Herb House will have its official opening in August 2019. Marigold plans to open an additional four Cannabis Houses in Portmore, Ocho Rios, Montego Bay, and Negril, pending CLA licence approval.

High Tide Inc. (CSE:HITI) (OTCQB:HITIF) today announced that its wholly-owned subsidiary, Famous Brandz Inc., recently signed its 9th license agreement with I.P.L. for access to various categories of its large Radio Days inventory of original images featuring historical celebrities, motion pictures, music albums, comics and other popular culture artwork. The Radio Days License grants Famous Brandz the right to reproduce and sell smoking accessories, including but not limited to bongs, containers, grinders, pipes, trays and vaporizers, to specialty retailers and distributors across North America over a term of 30 months.

Famous Brandz has begun the process of designing and producing a wide range of smoking accessories and cannabis lifestyle products featuring classic images of rock stars, pin-ups, sirens, horror movie characters and more. "Adding the Radio Days License to our existing stable of celebrity licenses, which include but are not limited to Snoop Dogg Pounds, Cheech & Chong's Up in Smoke, Trailer Park Boys, Sublime and Guns N' Roses, only strengthens Famous Brandz' industry leading position in licensed product manufacturing and wholesale distribution," said Raj Grover, President and Chief Executive Officer of High Tide.

"High Tide continues to grow on all fronts, domestically and abroad, and this new line of Famous Brandz products will leverage our vertical integration as well as our understanding of the cannabis customer," added Mr. Grover.

The Company also recently renewed its license with Da' Grassy High Inc. until the end of 2021, which grants Famous Brandz the right to manufacture, distribute and sell products featuring Kevin Smith's well known movie characters Jay & Silent Bob, Bluntman & Chronic and Buddy Christ. The DGH License is an important agreement for Famous Brandz as it has enabled the business to develop highly recognizable products that have been sold successfully on both a wholesale and retail basis around the world.  Based on the success of its celebrity licenses, High Tide expects to continue entering into agreements to reproduce popular brands and likenesses in the future.

SOL Global Investments Corp. (CSE: SOL) (OTC: SOLCF) announced that it has purchased an additional 16,766,250 common shares in the capital of HeavenlyRx Ltd. at a price of $0.40 for an aggregate subscription amount of CAD$23,909,000.

The subscription is part of a larger private offering by HeavenlyRx of Heavenly Shares and as a result of this subscription, SOL Global now holds 44.53% of the issued and outstanding Heavenly Shares and the other shareholders of Heavenly Rx collectively hold the remaining 55.47%. The Heavenly Shares are subject to an indefinite hold period under applicable Canadian securities laws.

"HeavenlyRx, through the expertise of the new management team under Paul Norman and their stream of acquisitions, is quickly becoming a dominant player in CBD wellness. This is a team and strategy we want to be part of in a large way. SOL Global's continued investment in HeavenlyRx has fast-tracked the on-boarding of highly relevant consumer brands to the company's portfolio ensuring their solid foundation as a leader in the CBD wellness" said Andy DeFrancesco, Chairman & Chief Investment Officer of SOL Global.

Heavenly Rx is a privately-held Hemp and CBD operating company focused on acquiring significant ownership interests at minimum, and a short-term mandate to gain absolute control with a 50.1% - 100% ownership, in various industry-leading THC-free companies in the cannabinoid wellness space.

HeavenlyRx's focus is on hemp cultivation, processing and the manufacturing of a diverse range of traditional CBD products including oils, tinctures, balms, and vape-ready products. Heavenly Rx will also own and operate its own retail locations along with health & wellness related studios where it will generate a repetitive captive audience with a desire for Heavenly Rx's products to be part of its customers' daily routine. It is expected that Heavenly Rx's portfolio will include several proprietary brands across numerous consumer product group verticals such as cosmetics and beauty products, bath and body products, and infused foods.

Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com  website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment   


Subscribe to the new cannabis podcast series:


To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and  sector trends  from Investorideas.com with our news alerts , articles , podcasts and videos  talking about cannabis,  crypto,  technology including  AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change Podcast and  the AI Eye Podcast and column covering developments in AI. 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.


Follow us on Social Media

Contact Investorideas.com
800-665-0411


  


Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directories





Friday, 26 July 2019

Investorideas.com - Chinese Government Approves Cannabis Pharmaceutical Joint Venture

Investorideas.com - Chinese Government Approves Cannabis Pharmaceutical Joint Venture

Investorideas.com - CannTrust (TSX: TRST, NYSE: CTST) Announces Senior Leadership Changes

Investorideas.com - CannTrust (TSX: TRST, NYSE: CTST) Announces Senior Leadership Changes

Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move (NASDAQ: $GWPH) (CSE: $CURA.C) (CSE: $OH.C) (NASDAQ: $OGI) (CSE: $CL.C)


Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move (NASDAQ: $GWPH) (CSE: $CURA.C) (CSE: $OH.C) (NASDAQ: $OGI) (CSE: $CL.C)



Delta, Kelowna, BC –July 26, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca  release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:



Today’s podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com “Potcast” featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today’s podcast we look at a few early announcements.

But first, The Cannabis Council of Canada responded to the draft regulation by the Quebec government to ban the sale of certain edible cannabis products and cannabis extracts:
"Yesterday's decision by the Quebec government to issue draft regulation with respect to edible cannabis products and cannabis extracts is extremely disappointing. If implemented, the efforts of the legal cannabis industry to replace the illicit market and keep cannabis out of the hands of minors will be severely hindered," said Megan McCrae, Board Chair, Cannabis Council of Canada.
The proposed regulation would ban the sale of treat, confectionery, dessert, and chocolate edible products and all products believed by the Quebec government to have a direct appeal to minors. In addition, a cannabis extract may not contain any additives or other substances intended to modify the odor, taste or color. In addition, it proposes to place a maximum cap of 30% THC on non-edible products, which will have the effect of curtailing other products – such as vape pens – from entering the Quebec market. The proposed regulation would also ban cannabis topicals.
The Cannabis Council of Canada strongly support the ethos of the proposed regulations, but its current form inhibits the legal, regulated cannabis industry from producing and selling a diversity of products in a controlled, responsible manner to Quebec cannabis consumers, and instead supports the illicit market for these products. The unregulated production and distribution of cannabis enriches organized crime and puts youth at risk. According to public opinion research conducted on behalf of the Cannabis Council of Canada, 64% of Quebecers support the legalization of cannabis, as well as safe, regulated access to cannabis products.
The Cannabis Council of Canada is the national voice for Canada's licensed cannabis producers which advocate for world-leading federal regulation and the safe, responsible production, access and use of recreational and medical cannabis products.

GW Pharmaceuticals plc (NASDAQ: GWPH) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorisation of EPIDYOLEX™ (cannabidiol oral solution) for use as adjunctive therapy of seizures associated with LennoxGastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients 2 years of age and older. The European Commission (EC) is expected to make a final decision on the marketing authorisation application (MAA) in approximately two months.

“Today’s positive CHMP opinion for EPIDYOLEX™ marks a major milestone for patients, and their families, battling to control two of the most severe and life-threatening forms of childhood onset epilepsy. Cannabidiol oral solution is the first in a new class of epilepsy medicines and the first plant-derived cannabis-based medicine to be submitted for European regulatory review, representing a historic breakthrough,” said Justin Gover, GW’s Chief Executive Officer. “We are excited by the potential to bring patients and physicians a rigorously tested and evaluated cannabis-based medicine with a documented safety and efficacy profile, manufactured to the highest standards and approved by a medicines regulator.”

“This is a significant milestone for patients with LGS and Dravet syndrome as there remains a severe unmet medical need for these rare, lifelong forms of epilepsy,” said Professor Martin Brodie, President, International Bureau for Epilepsy. “Today’s positive opinion brings hope to both patients and their families of a treatment option which has the potential to better control seizures and notably improve quality of life.”

“In my clinic, I often see patients with these highly treatment-resistant epilepsies who have tried and failed existing therapies. These patients and their families face a long and challenging road and very few achieve adequate seizure control,” said Dr Antonio Gil-Nagel Rein, Director of the Epilepsy Programme, Ruber International Hospital, Madrid. “Based on numerous clinical trials and the scrutiny of the European medicines regulator, this medicine has the potential to make a real difference to the lives of many patients.”

The CHMP’s positive opinion is based on results from four randomised, controlled Phase 3 trials. These studies incorporate data from more than 714 patients with either LGS or Dravet syndrome, two forms of epilepsy with high morbidity and mortality rates, which place a significant burden on families and caregivers. Many patients with LGS or Dravet syndrome have multiple seizures per day, which puts them at ongoing risk of falls and injury. Despite current anti-epileptic drug treatment, both of these severe forms of epilepsy remain highly treatment-resistant.

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) responded yesterday to a letter from the U.S. Food and Drug Administration ("FDA") informing FDA that the Company has addressed the issues that were raised in the letter regarding its CBD product marketing.

Upon receiving the letter, Curaleaf Hemp, the Company's hemp-based CBD product line, immediately began an extensive review of its website and social media platforms to remove all statements that FDA identified as non-compliant. This includes removing the Curaleaf Hemp blog, and the third-party links in it, and removing any statements and social media posts to which FDA had taken exception. Additionally, Curaleaf Hemp advised FDA that a number of the products mentioned in the FDA letter had previously been discontinued. Curaleaf Hemp will continue to work diligently to ensure that the information it provides to consumers on its website and social media platforms is fully compliant with FDA requirements.

"Our industry needs, wants and appreciates the work the FDA is doing to ensure there is regulation and compliance in the CBD marketplace," said Joseph Lusardi, CEO of Curaleaf.
"We care deeply about our customers and making a difference in our industry. Curaleaf is committed to being an ethical and responsible company and working with the FDA to be a leader in our industry, setting the standards and guidelines to best service our customers and the communities we serve."

Organigram Holdings Inc. (NASDAQ: OGI) (TSX-V: OGI) announced that it has entered into an advance payment and purchase agreement with 703454 N.B. Inc. (1812 Hemp) under which the Company will pre-fund hemp purchases to receive access to as much as 60,000 kilograms of dried hemp flower to be harvested in calendar 2019 for extraction into CBD isolate.

Organigram is already a party to a purchase agreement entered into in January 2019 with 1812 Hemp, in which Organigram was granted a right of first refusal on 1812 Hemp’s production of certain hemp cultivars.

“Access to a large, consistent volume of CBD-producing hemp has become increasingly important as Canadians express their demand for CBD-rich products for use in both recreational and medical capacities,” said Greg Engel, CEO, Organigram. “We’ve heard the call for CBD in the market and this agreement positions Organigram to meet that demand.”


CannaRoyalty Corp. d/b/a Origin House (CSE: OH) (OTCQX: ORHOF) announced today that it has divested its 5.1% equity interest in Alternative Medical Enterprises LLC for total consideration of US$6 Million. As Cresco Labs Inc. is prohibited under state law from acquiring additional positions in the Florida market, this divestment was a pre-closing condition to the Company's previously announced plan of arrangement pursuant to which Cresco has agreed to acquire all of the issued and outstanding shares of Origin House.

"With one of the final conditions to closing the Arrangement with Cresco now complete, we look forward to proceeding to drive value for shareholders as a combined company, upon the expiration of the anti-trust waiting period," commented Marc Lustig, Chairman and CEO of Origin House. "The sale of the remaining AltMed interest marks a significant milestone in the continued process whereby Origin House has monetized non-core holdings resulting in both substantial returns for shareholders and additional cash that has fueled the Company's growth."

The Company has received approximately US$3 million on close, with the remaining portion of approximately US$3 million, paid to Origin House in periodic installments, ending January 2020. Mr. Lustig has agreed with one of the purchasers that acquired 4.9% of the 5.1% Interest, Zola Global Investors Ltd., to personally repurchase a portion of their interest in AltMed under certain conditions. Zola is an operationally focused family office with deep expertise in investing across the legal cannabis sector, providing a source of capital for corporations divesting assets as part of their merger requirements.

Cresco Labs, Inc. (CSE: CL) (OTCQX: CRLBF) announced that it has obtained eligibility with The Depository Trust Company (DTC) for its common shares listed on the OTCQX.

“Our shareholders will now be able to electronically transfer shares between brokerages in the U.S.,” said Charles Bachtell, Co-founder and CEO of Cresco Labs. “DTC will allow for a more convenient trading experience for current and future shareholders, something we hope will have a positive impact on the liquidity and demand of our stock.”

Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com  website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment   


Subscribe to the new cannabis podcast series:


To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and  sector trends  from Investorideas.com with our news alerts , articles , podcasts and videos  talking about cannabis,  crypto,  technology including  AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change Podcast and  the AI Eye Podcast and column covering developments in AI. 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.


Follow us on Social Media

Contact Investorideas.com
800-665-0411

  




Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directories



Trial Could Position Eco-Friendly Fertilizer for Organic Cannabis Market

Trial Could Position Eco-Friendly Fertilizer for Organic Cannabis Market